NCT06633055View on ClinicalTrials.gov

A Phase I Clinical Trial of JH013 Injection

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy Subjects (HS)
Interventions
DRUG

JH013 injection

JH013 injection is a BAFF-R inhibitor monoclonal antibody

DRUG

Placebo

JH013 injections placebo

Sponsors
All Listed Sponsors
lead

Biotech Pharmaceutical Co., Ltd.

OTHER